Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing

10.1038/70995 ◽  
1999 ◽  
Vol 5 (12) ◽  
pp. 1418-1423 ◽  
Author(s):  
Michael K. Jones ◽  
Hongtao Wang ◽  
Brigitta M. Peskar ◽  
Ellis Levin ◽  
Rabiha M. Itani ◽  
...  
2000 ◽  
Vol 32 (7) ◽  
pp. 583-594 ◽  
Author(s):  
T. Brzozowski ◽  
P.Ch. Konturek ◽  
S.J. Konturek ◽  
Z. Sliwowski ◽  
D. Drozdowicz ◽  
...  

1995 ◽  
Vol 1 (2) ◽  
pp. 154-158 ◽  
Author(s):  
Lenard M. Lichtenberger ◽  
Zu-Mo Wang ◽  
Jimmy J. Romero ◽  
Carlos Ulloa ◽  
Joseph C. Perez ◽  
...  

2019 ◽  
Vol 4 (19) ◽  
pp. 5799-5809
Author(s):  
Dhruvi Patel ◽  
Krutarth Makwana ◽  
Manjusha B. Shirdhonkar ◽  
Ketan C. Kuperkar

1997 ◽  
Vol 25 (4) ◽  
pp. 190-195 ◽  
Author(s):  
Y Matsukawa ◽  
Y Tomita ◽  
S Nishinarita ◽  
T Horie ◽  
K Kato ◽  
...  

Beyond the obvious step of limiting use of non-steroidal anti-inflammatory drugs (NSAIDs), the treatment of ulcers induced by NSAIDs remains controversial. We evaluated the efficacy of the proton-pump inhibitor lansoprazole on NSAID-induced ulcers. Ulcers were endoscopically diagnosed in 47 NSAID users. These patients received 30 mg/day lansoprazole, orally, for 6 or 8 weeks (6 weeks for duodenal ulcers and 8 weeks for other ulcers). Ulcer healing was assessed using an established classification system. The presence of immunoglobulin G antibody against Helicobacter pylori was also evaluated. The antibody was present in the sera of 51% of patients (24/47). Most of the ulcers reached scarring stages S1 (healing) or S2 (good healing), and the S2 healing rate was 35%. Two H. pylori seropositive patients did not reach these stages; their ulcers were improved by H. pylori eradication therapy, followed, in one case, by medication with misoprostol. Lansoprazole seemed to be useful for most patients with NSAID-induced ulcers, but a few needed additional treatments.


Sign in / Sign up

Export Citation Format

Share Document